Navin Fluorine FY26 net profit jumps 130% to ₹663.56 crore
Navin Fluorine International Limited reported a 130% YoY rise in FY26 net profit to ₹663.56 crore, supported by a 41% increase in revenue to ₹3,313.90 crore. Q4 FY26 net profit grew 124% to ₹212.62 crore. The company is executing capex plans worth ₹431.5 crore across HFC, Specialty, and Advanced Materials segments.

*this image is generated using AI for illustrative purposes only.
Navin Fluorine International Limited has announced its financial results for the fiscal year ended March 31, 2026, reporting a 130% year-on-year increase in net profit to ₹663.56 crore. The company achieved this growth on the back of a 41% rise in revenue from operations, which reached ₹3,313.90 crore for FY26. The operating EBITDA for the year stood at ₹1,081.68 crore, marking a 103% YoY increase, with the margin expanding to 32.6%.
Financial Performance Overview
The company’s consolidated financial statements highlight robust growth across key metrics. Profit before tax for FY26 grew 130% to ₹873.17 crore. The operating profit before tax (PBT) saw a similar upward trend, increasing 142% to ₹814.63 crore. For the quarter ended March 31, 2026 (Q4 FY26), revenue from operations was ₹937.71 crore, a 34% increase from the corresponding quarter in the previous year. Net profit for Q4 FY26 rose 124% to ₹212.62 crore.
Segment and Operational Growth
Revenue growth was driven by performance across the company’s three primary business verticals: Hydrofluorocarbon Products (HPP), Specialty Chemicals, and Contract Development and Manufacturing Organization (CDMO). The HPP segment reported a 34% revenue growth for FY26, while Specialty Chemicals and CDMO grew 44% and 59% respectively. The company noted that the pricing environment for HFCs remained constructive throughout the year.
Capital Expenditure and Future Outlook
Navin Fluorine International is advancing several capital expenditure projects to support future growth. The company is investing ₹236.5 crore in additional HFC capacity equivalent to 15,000 MTPA of R32, expected to be commissioned by Q3FY27. Another project involving the de-bottlenecking of MPP capacity at Dahej, with a capex of ₹75 crore, is also targeted for commissioning in Q3FY27. Additionally, the company is setting up initial commercial capacity for advanced materials with a capex of ₹120 crore, targeted for Q1FY27.
Consolidated Financial Results (FY26)
| Particulars (₹ Crs.) | FY26 | FY25 | YoY Change |
|---|---|---|---|
| Net Revenue from Operations | 3,313.90 | 2,349.38 | 41% |
| Operating EBITDA | 1,081.68 | 533.72 | 103% |
| Operating EBITDA Margin | 32.6% | 22.7% | 992 Bps |
| Profit After Tax | 663.56 | 288.60 | 130% |
Corporate Governance and Investor Meet
The company has scheduled an analyst and institutional investor meet on June 02, 2026, as part of the Axis Capital Rising Stars Conference. The interaction will cover discussions based on publicly available information. Navin Fluorine continues to focus on expanding its footprint in emerging and innovative products while maintaining its commitment to environmental, social, and governance (ESG) standards.
Historical Stock Returns for Navin Fluorine International
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.09% | +3.37% | +11.79% | +19.29% | +66.94% | +122.73% |
How might the commissioning of 15,000 MTPA additional HFC capacity in Q3FY27 impact Navin Fluorine's market share amid potential global HFC pricing fluctuations?
What are the long-term revenue and margin targets for the advanced materials segment once the ₹120 crore initial commercial capacity goes live in Q1FY27?
Given the 59% CDMO revenue growth in FY26, which therapeutic areas or global pharma partnerships are likely to drive the next phase of CDMO expansion?


































